These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 4434291)

  • 21. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease.
    Funkiewiez A; Ardouin C; Krack P; Fraix V; Van Blercom N; Xie J; Moro E; Benabid AL; Pollak P
    Mov Disord; 2003 May; 18(5):524-30. PubMed ID: 12722166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease.
    Chastan N; Westby GW; Yelnik J; Bardinet E; Do MC; Agid Y; Welter ML
    Brain; 2009 Jan; 132(Pt 1):172-84. PubMed ID: 19001482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of levodopa on cognition of idiopathic Parkinson's disease].
    Alonso-Prieto E; Michel-Esteban E; Trujillo-Matienzo C; Palmero-Soler E
    Neurologia; 2004 Dec; 19(10):710-8. PubMed ID: 15568168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM; Lees AJ; Stern GM
    Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
    O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ
    Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson's disease.
    Cordato NJ; Halliday GM; Caine D; Morris JG
    Mov Disord; 2006 May; 21(5):632-8. PubMed ID: 16353177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Handwriting and speech changes across the levodopa cycle in Parkinson's disease.
    Poluha PC; Teulings HL; Brookshire RH
    Acta Psychol (Amst); 1998 Nov; 100(1-2):71-84. PubMed ID: 9844557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor structure, normative data and retest-reliability of a test of fine motor functions in patients with idiopathic Parkinson's disease.
    Ringendahl H
    J Clin Exp Neuropsychol; 2002 Jun; 24(4):491-502. PubMed ID: 12187462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of levodopa on handwriting tasks of different complexity in Parkinson's disease: a kinematic study.
    Zham P; Kumar D; Viswanthan R; Wong K; Nagao KJ; Arjunan SP; Raghav S; Kempster P
    J Neurol; 2019 Jun; 266(6):1376-1382. PubMed ID: 30877380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?
    Pillon B; Dubois B; Cusimano G; Bonnet AM; Lhermitte F; Agid Y
    J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):201-6. PubMed ID: 2703838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa and psychometric test performance in parkinsonism-5 years later.
    Riklan M; Whelihan W; Cullinan T
    Neurology; 1976 Feb; 26(2):173-9. PubMed ID: 814483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recognition memory in Parkinson's disease.
    Flowers KA; Pearce I; Pearce JM
    J Neurol Neurosurg Psychiatry; 1984 Nov; 47(11):1174-81. PubMed ID: 6502175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinsonian patients' self-reports of levodopa effects on cognitive and memory changes.
    Marsh GG; Markham CM; Treciokas L
    Psychosomatics; 1971; 12(2):114-6. PubMed ID: 5172948
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of levodopa therapy in patients with Parkinson's disease: statistical evidence for reduced tolerance to levodopa in the elderly.
    Grad B; Wener J; Rosenberg G; Wener SW
    J Am Geriatr Soc; 1974 Nov; 22(11):489-94. PubMed ID: 4418704
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.